Several international cancer societies and institutes recommend the use of ODx assay to risk-stratify patients with early HR-positive and HER2-negative BC and to predict the potential benefit of adding AC to ET, thus avoiding the use of expensive and toxic chemotherapy unnecessarily while ensuring the maximum benefit in patients who are at high risk of recurrence [12]. This evidence concerns the gene ERBB2 and breast cancer.